Compare COLD & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | TWST |
|---|---|---|
| Founded | 1903 | 2013 |
| Country | United States | United States |
| Employees | 12690 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2009 | 2018 |
| Metric | COLD | TWST |
|---|---|---|
| Price | $11.34 | $43.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $15.38 | ★ $48.75 |
| AVG Volume (30 Days) | ★ 4.7M | 1.1M |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.16% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,601,846,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $18.89 |
| Revenue Next Year | $2.66 | $15.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $10.10 | $23.30 |
| 52 Week High | $22.36 | $57.88 |
| Indicator | COLD | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 42.03 |
| Support Level | $10.31 | $42.89 |
| Resistance Level | $13.44 | $45.76 |
| Average True Range (ATR) | 0.40 | 2.64 |
| MACD | -0.19 | -0.91 |
| Stochastic Oscillator | 6.05 | 5.85 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 231 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.